Human cytomegalovirus (CMV)-induced memory-like NKG2C+ NK cells are transplantable and expand in vivo in response to recipient CMV antigen

Journal of Immunology

Volumn 189, Issue 10, 2012, Pages 5082-5088

  Foley, Bree ^a   Cooley, Sarah ^a   Verneris, Michael R ^a   Curtsinger, Julie ^a   Luo, Xianghua ^b,c   Waller, Edmund K ^d   Anasetti, Claudio ^e   Weisdorf, Daniel ^a   Miller, Jeffrey S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d EMORY UNIVERSITY   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2C; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CELL EXPANSION; CELL SURFACE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; DONOR; HUMAN; HUMAN CELL; IN VIVO STUDY; MAJOR CLINICAL STUDY; MEMORY CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECIPIENT; UPREGULATION; VIREMIA; VIRUS REACTIVATION;

ADULT; ANTIGENS, CD57; ANTIGENS, VIRAL; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOLOGIC MEMORY; KILLER CELLS, NATURAL; MALE; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; UP-REGULATION;

EID: 84868593211     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201964     Document Type: Article

References (31)

1. Bryceson, Y. T., M. E. March, H. G. Ljunggren, and E. O. Long. 2006. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol. Rev. 214: 73-91.
2. Lanier, L. L. 2008. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9: 495-502.
3. Moretta, A., C. Bottino, M. Vitale, D. Pende, R. Biassoni, M. C. Mingari, and L. Moretta. 1996. Receptors for HLA class-I molecules in human natural killer cells. Annu. Rev. Immunol. 14: 619-648.
4. Lanier, L. L. 1998. NK cell receptors. Annu. Rev. Immunol. 16: 359-393.
5. Braud, V. M., D. S. Allan, C. A. O'Callaghan, K. Söderström, A. D'Andrea, G. S. Ogg, S. Lazetic, N. T. Young, J. I. Bell, J. H. Phillips, et al. 1998. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391: 795-799.
6. Valés-Gómez, M., H. T. Reyburn, R. A. Erskine, M. López-Botet, and J. L. Strominger. 1999. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J. 18: 4250-4260.
7. Kärre, K., H. G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675-678.
8. Ljunggren, H. G., and K. Kärre. 1990. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today 11: 237-244.
9. Biron, C. A., K. S. Byron, and J. L. Sullivan. 1989. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320: 1731-1735.
10. Orange, J. S. 2002. Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect. 4: 1545-1558.
11. Crough, T., and R. Khanna. 2009. Immunobiology of human cytomegalovirus: from bench to bedside. Clin. Microbiol. Rev. 22: 76-98.
12. Gumá, M., A. Angulo, C. Vilches, N. Gómez-Lozano, N. Malats, and M. López-Botet. 2004. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104: 3664-3671.
13. + NK cells in response to human cytomegalovirus-infected fibroblasts. Blood 107: 3624-3631.
14. hi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl. Acad. Sci. USA 108: 14725-14732.
15. + natural killer cells with potent function. Blood 119: 2665-2674.
16. Björkström, N. K., T. Lindgren, M. Stoltz, C. Fauriat, M. Braun, M. Evander, J. Michaëlsson, K. J. Malmberg, J. Klingström, C. Ahlm, and H. G. Ljunggren. 2011. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J. Exp. Med. 208: 13-21.
17. Petitdemange, C., P. Becquart, N. Wauquier, V. Béziat, P. Debré, E. M. Leroy, and V. Vieillard. 2011. Unconventional repertoire profile is imprinted during acute chikungunya infection for natural killer cells polarization toward cyto-toxicity. PLoS Pathog. 7: e1002268.
18. Brunetta, E., M. Fogli, S. Varchetta, L. Bozzo, K. L. Hudspeth, E. Marcenaro, A. Moretta, and D. Mavilio. 2010. Chronic HIV-1 viremia reverses NKG2A/NKG2C ratio on natural killer cells in patients with human cytomegalovirus co-infection. AIDS 24: 27-34.
19. Thomas, R., H. Z. Low, K. Kniesch, R. Jacobs, R. E. Schmidt, and T. Witte. 2012. NKG2C deletion is a risk factor of HIV infection. AIDS Res. Hum. Retroviruses 28: 844-851.
20. Foley, B., S. Cooley, M. R. Verneris, J. Curtsinger, X. Luo, E. K. Waller, D. J. Weisdorf, and J. S. Miller. 2011. NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cyto-toxic functions. Blood 118: 2784-2792.
21. Kim, S., J. Poursine-Laurent, S. M. Truscott, L. Lybarger, Y. J. Song, L. Yang, A. R. French, J. B. Sunwoo, S. Lemieux, T. H. Hansen, and W. M. Yokoyama. 2005. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436: 709-713.
22. Sun, J. C., J. N. Beilke, and L. L. Lanier. 2009. Adaptive immune features of natural killer cells. Nature 457: 557-561.
23. Tomasec, P., V. M. Braud, C. Rickards, M. B. Powell, B. P. McSharry, S. Gadola, V. Cerundolo, L. K. Borysiewicz, A. J. McMichael, and G. W. Wilkinson. 2000. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 287: 1031.
24. Llano, M., M. Gumá, M. Ortega, A. Angulo, and M. López-Botet. 2003. Differential effects of US2, US6 and US11 human cytomegalovirus proteins on HLA class Ia and HLA-E expression: impact on target susceptibility to NK cell subsets. Eur. J. Immunol. 33: 2744-2754.
25. Zhou, W., J. Longmate, S. F. Lacey, J. M. Palmer, G. Gallez-Hawkins, L. Thao, R. Spielberger, R. Nakamura, S. J. Forman, J. A. Zaia, and D. J. Diamond. 2009. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood 113: 6465-6476.
26. Lundin, J., E. Kimby, M. Björkholm, P. A. Broliden, F. Celsing, V. Hjalmar, L. Möllgård, P. Rebello, G. Hale, H. Waldmann, et al. 2002. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100: 768-773.
27. Hillmen, P., A. B. Skotnicki, T. Robak, B. Jaksic, A. Dmoszynska, J. Wu, C. Sirard, and J. Mayer. 2007. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 25: 5616-5623.
28. Ikeda, H., L. J. Old, and R. D. Schreiber. 2002. The roles of IFN g in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13: 95-109.
29. Shankaran, V., H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson, L. J. Old, and R. D. Schreiber. 2001. IFNg and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.
30. Smyth, M. J., Y. Hayakawa, K. Takeda, and H. Yagita. 2002. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer 2: 850-861.
31. Biron, C. A., K. B. Nguyen, G. C. Pien, L. P. Cousens, and T. P. Salazar-Mather. 1999. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17: 189-220.